An example of this is pioglitazone (PGZ), which is a selective PPARγ agonist that, in addition to being used as an insulin sensitizer for the treatment of metabolic syndrome and T2D, has also been shown to be effective in non-alcoholic fatty liver disease, chronic kidney disease, inflammatory and autoimmune diseases, as well as central nervous system disorders and depression. This evidence concerns the gene INS and type 2 diabetes mellitus.